Barely Significant
← all excerpts

Biomarker study of pembrolizumab in patients with advanced rare cancers.

Cell Rep Med · 2026 · PMC13293929 · PMID 42167248

Europe PMCDOI
1
hedged sentence
0.0300
closest p · 0.6× alpha
0.0300
boldest claim

The sentences

nominally significantp = 0.030actually significant
In contrast, limited coordinated immune remodeling was observed between CB and NCB patients; only one population, CD3 + CD8 + PD-1 + PD-L1 + T cells, showed a nominally significant ( p = 0.030, q = 0.87, Wilcoxon rank-sum test) increase following treatment, preferentially in NCB patients ( Figure 5 B).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.